Información del producto
VLX600 is a mitochondria-targeted oxidative phosphorylation inhibitor that has been shown to inhibit the growth of cancer cells in vitro and in vivo. VLX600 has been shown to significantly kill tumour cells by inhibiting the production of ATP, which is necessary for cell division. VLX600 also prevents the formation of reactive oxygen species, which can damage DNA and proteins and lead to cell death. VLX600 has been shown to have significant cytotoxicity in various carcinoma cell lines, including human breast carcinoma, prostate carcinoma, and lung adenocarcinoma cell lines.
Vlx600 is a novel therapeutic agent for treatment of eye disorders such as age-related macular degeneration (AMD), retinal detachment, and dry eye syndrome (DES). This drug inhibits mitochondrial metabolism by binding to complex I of the electron transport chain, leading to increased levels of reactive oxygen species. This inhibition leads to decreased levels of ATP production and
Propiedades químicas
Consulta técnica sobre: 3D-CNA03155 VLX600
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
